Format

Send to

Choose Destination
J Nucl Med. 2017 Sep;58(Suppl 2):3S-9S. doi: 10.2967/jnumed.116.186502.

Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine.

Author information

1
Corporate Communications, Advanced Accelerator Applications, S.A., New York, New York; and rachel.levine@adacap.com.
2
Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands.

Abstract

In nuclear medicine, the term theranostics describes the combination of therapy and diagnostic imaging. In practice, this concept dates back more than 50 years; however, among the most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors. The development of these modalities through the radiolabeling of somatostatin analogs with various radionuclides has led to a revolution in patient management and established a foundation for expansion of the theranostic principle into other oncology indications. This article provides a review of the evolution and development of the theranostic radionuclide approach to the management of neuroendocrine tumors, as described by the inventor of this technique, Eric P. Krenning, in an interview with Rachel Levine.

KEYWORDS:

PRRT; PSMA; neuroendocrine; peptide; somatostatin

PMID:
28864612
DOI:
10.2967/jnumed.116.186502
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center